HALAVEN (eribulin mesylate) for Refractory Metastatic Breast Cancer - Cancer Therapy Advisor

HALAVEN (eribulin mesylate) for Refractory Metastatic Breast Cancer

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • halaven-eribulin-mesylate-drug-information-1091.JP

  • halaven-eribulin-mesylate-drug-information-11101.J

  • halaven-eribulin-mesylate-drug-information-12111.J

  • halaven-eribulin-mesylate-drug-information-13121.J

  • halaven-eribulin-mesylate-drug-information-14131.J

  • halaven-eribulin-mesylate-drug-information-15141.J

  • halaven-eribulin-mesylate-drug-information-16151.J

  • halaven-eribulin-mesylate-drug-information-17161.J

  • halaven-eribulin-mesylate-drug-information-18171.J

  • halaven-eribulin-mesylate-drug-information-19181.J

  • halaven-eribulin-mesylate-drug-information-20191.J

  • halaven-eribulin-mesylate-drug-information-21201.J

  • halaven-eribulin-mesylate-drug-information-22211.J

  • halaven-eribulin-mesylate-drug-information-23221.J

  • halaven-eribulin-mesylate-drug-information-24231.J

This slideshow reviews drug information for HALAVEN (eribulin mesylate), indicated for refractory metastatic breast cancer.
Table of Contents
Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 10: Clinical Pharmacology
Slide 14: Warnings and Precautions
Slide 16: Clinical Safety and Efficacy
Slide 22: Drug Storage and Supply
Slide 24: References

Next hm-slideshow in Slides